Patient
SITE014-0161
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE014 (NLD) (Dr. Moreau)
consented 2026-03-22
Adverse events
6
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 6
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-01 (study day 71); relationship: not assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-11-28 (study day 68); relationship: NOT RELATED
Grade 3 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-11-21 (study day 61); relationship: not assessed; serious criteria: hospitalization
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-11-17 (study day 57); relationship: NOT RELATED
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-11-13 (study day 53); relationship: NOT RELATED
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-10-15 (study day 24); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.